XML 27 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Value of Initial
Fixed $100 Investment
Based on:
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
Year
​ ​
Summary
Compensation
Table Total Pay
for CEO(1)(2)
Bill Sibold
​ ​
Summary
Compensation
Table Total Pay
for CEO(1)(2)
Paul A.
Friedman, M.D.
​ ​
CAP to
CEO(3)
Bill Sibold
​ ​
CAP to CEO(3)
Paul A.
Friedman, M.D.
​ ​
Average
Summary
Compensation
Table Total Pay
for Other
NEOs(1)(3)
​ ​
Average CAP
to Other
NEOs(1)(3)
​ ​
Company
TSR(4)
​ ​
Peer Group
TSR(4)
​ ​
GAAP Net
Income
(Loss)(5)
​ ​
Net
Product
Revenue(5)
​
​
2024
​ ​ ​ $ 12,214,250 ​ ​ ​ ​ ​ — ​ ​ ​ ​ $ 30,732,575 ​ ​ ​ ​ ​ — ​ ​ ​ ​ $ 5,472,667 ​ ​ ​ ​ $ 4,316,451 ​ ​ ​ ​ $ 339 ​ ​ ​ ​ $ 118 ​ ​ ​ ​ $ (465,892) ​ ​ ​ ​ $ 180,133 ​ ​
​
2023(6)
​ ​ ​ ​ 32,268,400 ​ ​ ​ ​ $ 9,563,286 ​ ​ ​ ​ ​ 42,282,414 ​ ​ ​ ​ $ 2,371,068 ​ ​ ​ ​ ​ 5,592,269 ​ ​ ​ ​ ​ (818,864) ​ ​ ​ ​ ​ 254 ​ ​ ​ ​ ​ 119 ​ ​ ​ ​ ​ (373,630) ​ ​ ​ ​ ​ — ​ ​
​
2022
​ ​ ​ ​ — ​ ​ ​ ​ ​ 5,395,385 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 38,419,031 ​ ​ ​ ​ ​ 4,104,196 ​ ​ ​ ​ ​ 29,641,482 ​ ​ ​ ​ ​ 319 ​ ​ ​ ​ ​ 114 ​ ​ ​ ​ ​ (295,250) ​ ​ ​ ​ ​ — ​ ​
​
2021
​ ​ ​ ​ — ​ ​ ​ ​ ​ 5,318,389 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,210,321 ​ ​ ​ ​ ​ 4,329,137 ​ ​ ​ ​ ​ 1,288,115 ​ ​ ​ ​ ​ 93 ​ ​ ​ ​ ​ 126 ​ ​ ​ ​ ​ (241,846) ​ ​ ​ ​ ​ — ​ ​
​
2020
​ ​ ​ ​ — ​ ​ ​ ​ ​ 4,535,446 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 6,480,322 ​ ​ ​ ​ ​ 3,677,403 ​ ​ ​ ​ ​ 5,646,095 ​ ​ ​ ​ ​ 122 ​ ​ ​ ​ ​ 126 ​ ​ ​ ​ ​ (202,244) ​ ​ ​ ​ ​ — ​ ​
(1)
Bill Sibold was appointed CEO effective September 8, 2023; Paul Friedman, M.D. served as CEO through September 8, 2023. For 2022, 2021, and 2020, the CEO was Dr. Friedman. For 2024, the other NEOs were Mardi Dier, Rebecca Taub, M.D., Carole Huntsman, Shannon Kelley, Alex Howarth and Brian Lynch. For 2023, the other NEOs were Rebecca Taub, M.D., Brian Lynch, Alex Howarth, Carole Huntsman and Remy Sukhija. For 2022, the other NEOs were Rebecca Taub, M.D., Brian Lynch, Remy Sukhija and Alex Howarth. For 2021, the other NEOs were Rebecca Taub, M.D., Brian Lynch, Remy Sukhija, Alex Howarth and Marc Schneebaum. For 2020, the other NEOs were Rebecca Taub, M.D., Brian Lynch, Remy Sukhija and Marc Schneebaum.
​
(2)
The values reflected in this column reflect the “Total” compensation set forth in the Summary Compensation Table (for purposes of this Pay Versus Performance section, “SCT”) on page 46 of this proxy statement. See the footnotes to the SCT for further detail regarding the amounts in this column.
​
(3)
CAP is defined by the SEC and is computed in accordance with SEC rules by subtracting the amounts in the “Stock Awards” ​(as applicable) and “Option Awards” column of the SCT for each year from the “Total” column of the SCT and then: (i) adding the fair value as of the end of the reported year of all awards granted during the reporting year that are outstanding and unvested as of the end of the reporting year; (ii) adding the amount equal to the change as of the end of the reporting year (from the end of the prior year) in fair value (whether positive or negative) of any awards granted in any prior year that are outstanding and unvested as of the end of the reporting year; (iii) adding, for awards that are granted and vest in the reporting year, the fair value as of the vesting date; (iv) adding the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value (whether positive or negative) of any awards granted in any prior year for which all applicable vesting conditions were satisfied at the end of or during the reporting year; and (v) subtracting, for any awards granted in any prior year that are forfeited during the reporting year, the amount equal to the fair value at the end of the prior year. Valuation assumptions used to calculate fair values did not materially differ from those used to calculate fair values at the time of grant as reflected in the Summary Compensation Table. The tables below reflect the adjustments made to the SCT total compensation to compute CAP for our CEO and average CAP for our other NEOs.
​
(4)
Reflects the cumulative TSR of the Company and the Nasdaq Biotechnology Index for the year ended December 31, 2020, the two-years ended December 31, 2021, the three years ended December 31, 2022, the four years ended December 31, 2023, and the five years ended December 31, 2024, assuming a $100 investment at the closing price on December 31, 2019 and the reinvestment of all dividends.
​
(5)
Amounts in thousands.
​
(6)
Amounts reported for 2023 have been revised from the numbers previously reported in last year’s “Pay Versus Performance” table in order to adjust the methodology for the calculation of the fair values of PSUs and option awards consistent with SEC guidance.
​
CEO (Mr. Sibold)
​
Year
​ ​
SCT Total
Compensation
​ ​
Minus SCT
Equity Awards
​ ​
Plus Year-End Fair Value of
Equity Awards Granted
During Year That Remained
Unvested as of Last
Day of Year
​ ​
Plus Change in Fair
Value from Last Day
of Prior Year to
Last Day of Year of
Unvested Equity Awards
​ ​
Plus Change in Fair
Value from Last Day of
Prior Year to Vesting
Date of Unvested Equity
Awards that Vested
During Year
​ ​
Equals CAP
​
​
2024
​ ​ ​ $ 12,214,250 ​ ​ ​ ​ $ (10,363,804) ​ ​ ​ ​ $ 13,884,294 ​ ​ ​ ​ $ 14,841,460 ​ ​ ​ ​ $ 156,375 ​ ​ ​ ​ $ 30,732,575 ​ ​
​
2023
​ ​ ​ ​ 32,268,400 ​ ​ ​ ​ ​ (31,205,000) ​ ​ ​ ​ ​ 41,219,014 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 42,282,414 ​ ​
CEO (Dr. Friedman)
​
Year
​ ​
SCT Total
Compensation
​ ​
Minus SCT
Equity Awards
​ ​
Plus Year-End Fair Value of
Equity Awards Granted
During Year That Remained
Unvested as of Last
Day of Year
​ ​
Plus Change in Fair
Value from Last Day
of Prior Year to
Last Day of Year of
Unvested Equity Awards
​ ​
Plus Change in Fair
Value from Last Day of
Prior Year to Vesting Date
of Unvested Equity Awards
that Vested During Year
​ ​
Equals CAP
​
​
2023
​ ​ ​ $ 9,563,286 ​ ​ ​ ​ $ (7,999,867) ​ ​ ​ ​ $ 6,170,442 ​ ​ ​ ​ $ (3,271,953) ​ ​ ​ ​ $ (2,090,840) ​ ​ ​ ​ $ 2,371,068 ​ ​
​
2022
​ ​ ​ ​ 5,395,385 ​ ​ ​ ​ ​ (4,239,900) ​ ​ ​ ​ ​ 18,078,963 ​ ​ ​ ​ ​ 9,291,946 ​ ​ ​ ​ ​ 9,892,637 ​ ​ ​ ​ ​ 38,419,031 ​ ​
​
2021
​ ​ ​ ​ 5,318,389 ​ ​ ​ ​ ​ (4,267,500) ​ ​ ​ ​ ​ 2,696,917 ​ ​ ​ ​ ​ (1,228,699) ​ ​ ​ ​ ​ (1,308,786) ​ ​ ​ ​ ​ 1,210,321 ​ ​
​
2020
​ ​ ​ ​ 4,535,446 ​ ​ ​ ​ ​ (3,468,500) ​ ​ ​ ​ ​ 4,187,875 ​ ​ ​ ​ ​ 584,964 ​ ​ ​ ​ ​ 640,537 ​ ​ ​ ​ ​ 6,480,322 ​ ​
Other NEOs (Average)
​
Year
​ ​
SCT Total
Compensation
​ ​
Minus SCT
Equity Awards
​ ​
Plus
Year-End Fair
Value of Equity
Awards Granted
During Year That
Remained
Unvested as of
Last Day of Year
​ ​
Plus
Change in Fair
Value from Last
Day of Prior
Year to Last
Day of Year of
Unvested
Equity Awards
​ ​
Plus
Fair Value at
Vesting of
Equity Awards
Granted and
Vested
During Year
​ ​
Plus
Change in Fair
Value from Last
Day of Prior Year
to Vesting Date of
Unvested Equity
Awards that
Vested During
Year
​ ​
Minus
Fair Value at Last
Day of Prior Year
of Equity Awards
Granted in Prior
Years that Failed
to Meet Vesting
Conditions During
Year
​ ​
Equals CAP
​
​
2024
​ ​ ​ $ 5,472,667 ​ ​ ​ ​ $ (4,487,648) ​ ​ ​ ​ $ 4,283,685 ​ ​ ​ ​ $ 518,348 ​ ​ ​ ​ $ 111,503 ​ ​ ​ ​ $ (248,606) ​ ​ ​ ​ $ (1,333,498) ​ ​ ​ ​ $ 4,316,451 ​ ​
​
2023
​ ​ ​ ​ 5,592,269 ​ ​ ​ ​ ​ (4,509,651) ​ ​ ​ ​ ​ 3,004,087 ​ ​ ​ ​ ​ (1,790,661) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (2,199,912) ​ ​ ​ ​ ​ (914,997) ​ ​ ​ ​ ​ (818,864) ​ ​
​
2022
​ ​ ​ ​ 4,104,196 ​ ​ ​ ​ ​ (3,292,689) ​ ​ ​ ​ ​ 14,322,661 ​ ​ ​ ​ ​ 8,017,461 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 6,489,853 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 29,641,482 ​ ​
​
2021
​ ​ ​ ​ 4,329,137 ​ ​ ​ ​ ​ (3,558,540) ​ ​ ​ ​ ​ 1,814,098 ​ ​ ​ ​ ​ (646,123) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (650,457) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,288,115 ​ ​
​
2020
​ ​ ​ ​ 3,677,403 ​ ​ ​ ​ ​ (2,936,490) ​ ​ ​ ​ ​ 3,343,083 ​ ​ ​ ​ ​ 1,291,002 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 271,097 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 5,646,095 ​ ​
       
Company Selected Measure Name Net Product Revenue        
Named Executive Officers, Footnote
(1)
Bill Sibold was appointed CEO effective September 8, 2023; Paul Friedman, M.D. served as CEO through September 8, 2023. For 2022, 2021, and 2020, the CEO was Dr. Friedman. For 2024, the other NEOs were Mardi Dier, Rebecca Taub, M.D., Carole Huntsman, Shannon Kelley, Alex Howarth and Brian Lynch. For 2023, the other NEOs were Rebecca Taub, M.D., Brian Lynch, Alex Howarth, Carole Huntsman and Remy Sukhija. For 2022, the other NEOs were Rebecca Taub, M.D., Brian Lynch, Remy Sukhija and Alex Howarth. For 2021, the other NEOs were Rebecca Taub, M.D., Brian Lynch, Remy Sukhija, Alex Howarth and Marc Schneebaum. For 2020, the other NEOs were Rebecca Taub, M.D., Brian Lynch, Remy Sukhija and Marc Schneebaum.
       
Peer Group Issuers, Footnote
(4)
Reflects the cumulative TSR of the Company and the Nasdaq Biotechnology Index for the year ended December 31, 2020, the two-years ended December 31, 2021, the three years ended December 31, 2022, the four years ended December 31, 2023, and the five years ended December 31, 2024, assuming a $100 investment at the closing price on December 31, 2019 and the reinvestment of all dividends.
       
Adjustment To PEO Compensation, Footnote
(3)
CAP is defined by the SEC and is computed in accordance with SEC rules by subtracting the amounts in the “Stock Awards” ​(as applicable) and “Option Awards” column of the SCT for each year from the “Total” column of the SCT and then: (i) adding the fair value as of the end of the reported year of all awards granted during the reporting year that are outstanding and unvested as of the end of the reporting year; (ii) adding the amount equal to the change as of the end of the reporting year (from the end of the prior year) in fair value (whether positive or negative) of any awards granted in any prior year that are outstanding and unvested as of the end of the reporting year; (iii) adding, for awards that are granted and vest in the reporting year, the fair value as of the vesting date; (iv) adding the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value (whether positive or negative) of any awards granted in any prior year for which all applicable vesting conditions were satisfied at the end of or during the reporting year; and (v) subtracting, for any awards granted in any prior year that are forfeited during the reporting year, the amount equal to the fair value at the end of the prior year. Valuation assumptions used to calculate fair values did not materially differ from those used to calculate fair values at the time of grant as reflected in the Summary Compensation Table. The tables below reflect the adjustments made to the SCT total compensation to compute CAP for our CEO and average CAP for our other NEOs.
CEO (Mr. Sibold)
​
Year
​ ​
SCT Total
Compensation
​ ​
Minus SCT
Equity Awards
​ ​
Plus Year-End Fair Value of
Equity Awards Granted
During Year That Remained
Unvested as of Last
Day of Year
​ ​
Plus Change in Fair
Value from Last Day
of Prior Year to
Last Day of Year of
Unvested Equity Awards
​ ​
Plus Change in Fair
Value from Last Day of
Prior Year to Vesting
Date of Unvested Equity
Awards that Vested
During Year
​ ​
Equals CAP
​
​
2024
​ ​ ​ $ 12,214,250 ​ ​ ​ ​ $ (10,363,804) ​ ​ ​ ​ $ 13,884,294 ​ ​ ​ ​ $ 14,841,460 ​ ​ ​ ​ $ 156,375 ​ ​ ​ ​ $ 30,732,575 ​ ​
​
2023
​ ​ ​ ​ 32,268,400 ​ ​ ​ ​ ​ (31,205,000) ​ ​ ​ ​ ​ 41,219,014 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 42,282,414 ​ ​
CEO (Dr. Friedman)
​
Year
​ ​
SCT Total
Compensation
​ ​
Minus SCT
Equity Awards
​ ​
Plus Year-End Fair Value of
Equity Awards Granted
During Year That Remained
Unvested as of Last
Day of Year
​ ​
Plus Change in Fair
Value from Last Day
of Prior Year to
Last Day of Year of
Unvested Equity Awards
​ ​
Plus Change in Fair
Value from Last Day of
Prior Year to Vesting Date
of Unvested Equity Awards
that Vested During Year
​ ​
Equals CAP
​
​
2023
​ ​ ​ $ 9,563,286 ​ ​ ​ ​ $ (7,999,867) ​ ​ ​ ​ $ 6,170,442 ​ ​ ​ ​ $ (3,271,953) ​ ​ ​ ​ $ (2,090,840) ​ ​ ​ ​ $ 2,371,068 ​ ​
​
2022
​ ​ ​ ​ 5,395,385 ​ ​ ​ ​ ​ (4,239,900) ​ ​ ​ ​ ​ 18,078,963 ​ ​ ​ ​ ​ 9,291,946 ​ ​ ​ ​ ​ 9,892,637 ​ ​ ​ ​ ​ 38,419,031 ​ ​
​
2021
​ ​ ​ ​ 5,318,389 ​ ​ ​ ​ ​ (4,267,500) ​ ​ ​ ​ ​ 2,696,917 ​ ​ ​ ​ ​ (1,228,699) ​ ​ ​ ​ ​ (1,308,786) ​ ​ ​ ​ ​ 1,210,321 ​ ​
​
2020
​ ​ ​ ​ 4,535,446 ​ ​ ​ ​ ​ (3,468,500) ​ ​ ​ ​ ​ 4,187,875 ​ ​ ​ ​ ​ 584,964 ​ ​ ​ ​ ​ 640,537 ​ ​ ​ ​ ​ 6,480,322 ​ ​
       
Non-PEO NEO Average Total Compensation Amount $ 5,472,667 $ 5,592,269 $ 4,104,196 $ 4,329,137 $ 3,677,403
Non-PEO NEO Average Compensation Actually Paid Amount $ 4,316,451 (818,864) 29,641,482 1,288,115 5,646,095
Adjustment to Non-PEO NEO Compensation Footnote
(3)
CAP is defined by the SEC and is computed in accordance with SEC rules by subtracting the amounts in the “Stock Awards” ​(as applicable) and “Option Awards” column of the SCT for each year from the “Total” column of the SCT and then: (i) adding the fair value as of the end of the reported year of all awards granted during the reporting year that are outstanding and unvested as of the end of the reporting year; (ii) adding the amount equal to the change as of the end of the reporting year (from the end of the prior year) in fair value (whether positive or negative) of any awards granted in any prior year that are outstanding and unvested as of the end of the reporting year; (iii) adding, for awards that are granted and vest in the reporting year, the fair value as of the vesting date; (iv) adding the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value (whether positive or negative) of any awards granted in any prior year for which all applicable vesting conditions were satisfied at the end of or during the reporting year; and (v) subtracting, for any awards granted in any prior year that are forfeited during the reporting year, the amount equal to the fair value at the end of the prior year. Valuation assumptions used to calculate fair values did not materially differ from those used to calculate fair values at the time of grant as reflected in the Summary Compensation Table. The tables below reflect the adjustments made to the SCT total compensation to compute CAP for our CEO and average CAP for our other NEOs.
Other NEOs (Average)
​
Year
​ ​
SCT Total
Compensation
​ ​
Minus SCT
Equity Awards
​ ​
Plus
Year-End Fair
Value of Equity
Awards Granted
During Year That
Remained
Unvested as of
Last Day of Year
​ ​
Plus
Change in Fair
Value from Last
Day of Prior
Year to Last
Day of Year of
Unvested
Equity Awards
​ ​
Plus
Fair Value at
Vesting of
Equity Awards
Granted and
Vested
During Year
​ ​
Plus
Change in Fair
Value from Last
Day of Prior Year
to Vesting Date of
Unvested Equity
Awards that
Vested During
Year
​ ​
Minus
Fair Value at Last
Day of Prior Year
of Equity Awards
Granted in Prior
Years that Failed
to Meet Vesting
Conditions During
Year
​ ​
Equals CAP
​
​
2024
​ ​ ​ $ 5,472,667 ​ ​ ​ ​ $ (4,487,648) ​ ​ ​ ​ $ 4,283,685 ​ ​ ​ ​ $ 518,348 ​ ​ ​ ​ $ 111,503 ​ ​ ​ ​ $ (248,606) ​ ​ ​ ​ $ (1,333,498) ​ ​ ​ ​ $ 4,316,451 ​ ​
​
2023
​ ​ ​ ​ 5,592,269 ​ ​ ​ ​ ​ (4,509,651) ​ ​ ​ ​ ​ 3,004,087 ​ ​ ​ ​ ​ (1,790,661) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (2,199,912) ​ ​ ​ ​ ​ (914,997) ​ ​ ​ ​ ​ (818,864) ​ ​
​
2022
​ ​ ​ ​ 4,104,196 ​ ​ ​ ​ ​ (3,292,689) ​ ​ ​ ​ ​ 14,322,661 ​ ​ ​ ​ ​ 8,017,461 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 6,489,853 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 29,641,482 ​ ​
​
2021
​ ​ ​ ​ 4,329,137 ​ ​ ​ ​ ​ (3,558,540) ​ ​ ​ ​ ​ 1,814,098 ​ ​ ​ ​ ​ (646,123) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (650,457) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,288,115 ​ ​
​
2020
​ ​ ​ ​ 3,677,403 ​ ​ ​ ​ ​ (2,936,490) ​ ​ ​ ​ ​ 3,343,083 ​ ​ ​ ​ ​ 1,291,002 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 271,097 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 5,646,095 ​ ​
       
Compensation Actually Paid vs. Total Shareholder Return [MISSING IMAGE: bc_tsr-pn.jpg]        
Compensation Actually Paid vs. Net Income
[MISSING IMAGE: bc_netincome-pn.jpg]
       
Compensation Actually Paid vs. Company Selected Measure
[MISSING IMAGE: bc_netproduct-pn.jpg]
       
Total Shareholder Return Vs Peer Group [MISSING IMAGE: bc_tsr-pn.jpg]        
Tabular List, Table
Tabular List of Performance Measures
Compensation for our NEOs is determined based on a variety of factors, as further discussed in the CD&A section of this proxy statement. The tabular list of financial performance measures included and defined below is used by the Company to link CAP to Company performance. We did not use any other metrics to directly link CAP to Company performance in 2024.
•
Net product revenue
       
Total Shareholder Return Amount $ 339 254 319 93 122
Peer Group Total Shareholder Return Amount 118 119 114 126 126
Net Income (Loss) $ (465,892,000) $ (373,630,000) $ (295,250,000) $ (241,846,000) $ (202,244,000)
Company Selected Measure Amount 180,133,000
PEO Name Bill Sibold        
Measure:: 1          
Pay vs Performance Disclosure          
Name Net product revenue        
Bill Sibold [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount $ 12,214,250 $ 32,268,400
PEO Actually Paid Compensation Amount 30,732,575 42,282,414
Paul A.Friedman [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount 9,563,286 5,395,385 5,318,389 4,535,446
PEO Actually Paid Compensation Amount 2,371,068 38,419,031 1,210,321 6,480,322
PEO | Bill Sibold [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (10,363,804) (31,205,000)      
PEO | Bill Sibold [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 13,884,294 41,219,014      
PEO | Bill Sibold [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 14,841,460      
PEO | Bill Sibold [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 156,375      
PEO | Paul A.Friedman [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount   (7,999,867) (4,239,900) (4,267,500) (3,468,500)
PEO | Paul A.Friedman [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount   6,170,442 18,078,963 2,696,917 4,187,875
PEO | Paul A.Friedman [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount   (3,271,953) 9,291,946 (1,228,699) 584,964
PEO | Paul A.Friedman [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount   (2,090,840) 9,892,637 (1,308,786) 640,537
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (4,487,648) (4,509,651) (3,292,689) (3,558,540) (2,936,490)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 4,283,685 3,004,087 14,322,661 1,814,098 3,343,083
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 518,348 (1,790,661) 8,017,461 (646,123) 1,291,002
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 111,503        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (248,606) (2,199,912) $ 6,489,853 $ (650,457) $ 271,097
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (1,333,498) $ (914,997)